What is Touchlight Genetics?
Touchlight Genetics is a privately-owned biotechnology firm headquartered in London, U.K., dedicated to the discovery and development of DNA-based genetic medicines. The company's core innovation lies in its proprietary "doggybone" or dbDNA synthetic DNA vector technology, which serves as a foundational element for its DNA vaccines and gene therapies. Established in 2007, Touchlight Genetics operates from its base in Hampton, London, positioning itself at the forefront of advancements in genetic medicine.
How much funding has Touchlight Genetics raised?
Touchlight Genetics has raised a total of $58M across 1 funding round:
Other Financing Round
$58M
Other Financing Round (2021): $58M with participation from Bridford Investments Limited
Key Investors in Touchlight Genetics
Bridford Investments Limited
Bridford Investments Limited is an investor participating in the funding round, with its specific focus area not detailed.
What's next for Touchlight Genetics?
The recent major strategic investment in Touchlight Genetics signals a pivotal moment for the company, likely enabling it to accelerate its research and development pipelines, scale its manufacturing capabilities, and potentially expand its therapeutic offerings. This enterprise-level funding suggests a transition towards broader clinical validation and commercialization efforts, positioning Touchlight Genetics for significant growth and impact in the rapidly evolving field of genetic therapies and DNA-based medicines.
See full Touchlight Genetics company page
